No Data
No Data
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
Should Viking (VKTX) Stock Be in Your Portfolio Pre-Q2 Earnings?
The biotech firm’s performance has been mixed over the trailing four quarters.
Is Viking Therapeutics a Millionaire-Maker?
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
No Data